Coronary Heart Disease in Women Go Red for Women

Similar documents
Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Professor Norman Sharpe. Heart Foundation West Coast

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Controversies in Primary Care Pros and Cons of HRT on patients with CHD

Ischaemic Heart Disease

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Primary Prevention of Stroke

Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Hormone therapy. Dr. med. Frank Luzuy

Heart Disease in Women: Is it Really Different?

WHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro

Dyslipidemia in women: Who should be treated and how?

Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

Preventive Cardiology Scientific evidence

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Diabetes Mellitus: A Cardiovascular Disease

The Clinical Unmet need in the patient with Diabetes and ACS

Menopause and HRT. John Smiddy and Alistair Ledsam

Is Lower Better for LDL or is there a Sweet Spot

Women and Vascular Disease

Estrogens vs Testosterone for cardiovascular health and longevity

Associate Professor Gerry Devlin

HT: Where do we stand after WHI?

Sex, hormones and the heart

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital

Current Issues in Cardiovascular Risk Management. Les Toop Norman Sharpe June 2014

Potential dangers of hormone replacement therapy in women at high risk

Vascular Diseases. Overview: Selected Slides

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

HORMONE REPLACEMENT THERAPY

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Cardiovascular Risk Assessment and Management Making a Difference

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Women & Heart Disease Prevention

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

New Paradigms in Predicting CVD Risk

Coronary Heart Disease

Menopausal hormone therapy currently has no evidence-based role for

How would you manage Ms. Gold

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Estrogen and progestogen therapy in postmenopausal women

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Disclosures. May 15 th, Influenza Vaccination as Secondary Prevention for Acute Coronary Events Where do we need to go in clinical practice?

Heart disease in Women

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Women and Heart Disease

Optimal medical therapy in patients with stable CAD

Ms. Y. Outline. Updates of SERMs and Estrogen

1. Which one of the following patients does not need to be screened for hyperlipidemia:

Practice-Level Executive Summary Report

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

4. Which survey program does your facility use to get your program designated by the state?

Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal

Quality Payment Program: Cardiology Specialty Measure Set

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

Financial Conflicts of Interest

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Cardiovascular Disease

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

LDL cholesterol and cardiovascular outcomes?

Menopause management NICE Implementation

Haemostasis, thrombosis risk and hormone replacement therapy

surtout qui n est PAS à risque?

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Quality Payment Program: Cardiology Specialty Measure Set

The TNT Trial Is It Time to Shift Our Goals in Clinical

Red Alert for Women s Hearts Women and Cardiovascular Research in Europe

The Failing Heart in Primary Care

The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University

Something has changed? The literature from 2008 to present?

Environmental. Vascular / Tissue. Metabolics

Statins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK

Diabetes and the Heart

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

Supplement materials:

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Chest Pain. Dr Robert Huggett Consultant Cardiologist

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Heart Disease in Women: Diagnostic Approaches and Management

CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN

Population models of health impact of combination polypharmacy

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

CVD Prevention, Who to Consider

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Transcription:

Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group

Women are Different from Men Sex Differences biological differences Gender Differences the effect of Social Environmental Community

Leading Causes of Death in New Zealand, 2011 Males Females Total % % % Cause Males Females Total Coronary heart disease% 24 % 21 % 22 Coronary Heart 19.6 16.9 18.3 Other Disease diseases of the 7 10 8 Cerebrovascular 6.8 10.8 8.8 heart Disease and circulation Cerebrovascular Cancer disease 31.1 8 27.6 13 29 10 Breast Cancer 4.1 Cancer 30 27 29

Perception of Risk of Myocardial Infarction North American telephone survey 44% women thought they were unlikely to have a myocardial infarction in their lifetime 55% perceived their risk of breast cancer to be equal or greater than the risk of heart disease Wenger. Int J Fertil 1998; 43: 84-90.

Age Standardised Mortality of New Zealand Women per 100,000 Maori and non Maori, 2011 Rate per 100,000 Maori Non Maori Total Coronary heart disease 56 IHD 95.5 44.1 47.3 Cerebrovascular Disease 38.5 29.4 30.6 Hypertensive disease 3 Breast Cancer 27.3 17.4 18.3 Cerebrovascular disease 32 Breast cancer 21

ANZACS-QI National ACS report/ ACS Incidence

Delay in Seeking Treatment for Cardiac Symptoms - Gender Differences Women suffering an acute myocardial infarction present later to hospital Sonke. BMJ 1996;313:853-5

Reasons for Delay in Presentation with Symptoms of Heart Disease Difficulty recognising symptoms Self-treatment Obtaining reassurance Using traditional coping strategies for menstruation and child-birth Cheryl Campbell, 2005. PhD thesis

The Difficulty in Diagnosis

Symptomatic Presentation of Women with ACS Often atypical Fatigue Sleep disturbance SOB

Prodromal Symptoms (1/12 pre ACS) 515 Women with AMI 70.7% unusual fatigue (severe) 47.8% sleep disturbance (severe) 42.1% SOB 39.4% indigestion 35.5% anxiety 29.7% chest discomfort McSweeney JC et al. Circulation 2003. 108: 2619-23

Acute Symptoms 515 Women with AMI 57.9% SOB 54.8% weakness 42.9% fatigue 43% no chest pain 39% cold sweat 39% dizziness McSweeney JC et al. Circulation 2003. 108: 2619-23

Chest Pain at Presentation 515 Women with AMI Description pressure, ache or severe tightness in the chest Location 37% back 27.7% high chest McSweeney JC et al. Circulation 2003. 108: 2619-23

WISE Study Women s Ischaemic Syndrome Evaluation Symptomatic Presentation Typical symptoms More common in older women Atypical Symptoms Fatigue Sleep disturbance SOB Functional Limitation (< 4.7Mets) Highly predictive future cardiovascular event (67% events)

Risk Factors for Cardiovascular Events in Women

WISE Study Risk Factors for Cardiovascular Events in Women Diabetes Metabolic syndrome (not BMI) + hscrp = DM risk hscrp Hb < 120g/l SBP (premenopause) RR 5.6 (2.18 14.3) Oestrogen deficiency premenopause (anovulatory cycles) RR 7.4 (1.7 33.3)

Secondary Prevention

Sex Related Disparities in Care after Hospitalization for CAD >65 49,358 registry patients Get With the Guidelines CAD, US Aspirin within 24 hours Aspirin on hospital discharge Beta blocker on discharge ACEI/ARB on discharge Smoking cessation counselling Lipid lowering medication Li et al. Circ Cardiovasc Qual Outcomes. 2016;9:S36-44

Sex Related Disparities in Care after Hospitalization for CAD >65 Women were Less likely to receive optimal care OR=0.92 (0.88-0.95, p<0.0001) More likely to have higher mortality than men who received suboptimal care OR=1.25 (1.00-1.55, p=0.05) 69% of sex disparity may be reduced by providing optimal care to women Li et al. Circ Cardiovasc Qual Outcomes. 2016;9:S36-44

Statin Treatment in Women Cholesterol Treatment Trialists 174,149 patients 46,675 women 22 trials statin vs control 124,537 patients 5 trials more intense vs less intense statin CTT. Lancet 2015; 385: 1397-1405

Cholesterol Treatment Trialists Effects on Major Cardiovascular Events per 1mmol/l LDL

Secondary Prevention Women suffer more depression and have higher rates of mental stress induced ischaemia Women are less likely to attend cardiac rehabilitation

Primary Prevention

HRT and Cardiovascular Events WHI < 5 years E + P Placebo HR(95% CI) CHD 195 (0.41%) 153 (0.34%) 1.23 (0.99 1.53) Stroke 159 (0.33%) 112 (0.25%) 1.31 (1.03-1.68) E Placebo CHD 201 (0.54%) 217 (0.57%) 0.95 (0.78-1.16) Stroke 168 (0.45%) 127 (0.33%) 1.33 (1.05-1.68) Rossouw JAMA 2007;297:1465-1477

Difference in events for hormone users v placebo aged 50-59 after 5 years E+P v placebo E v placebo Participant yrs (13,728) (12,967) (7,934) (8,140) Event E+P extra events E+P hazard ratio E extra events E hazard ratio CHD +11 1.49(0.86-2.59) -5 0.69(0.32-1.48) VTE +29 2.27(1.19-4.33) +5 1.37(0.70-2.68) Am J Med 2005;18:79S-87S,JAMA 2004;292:1573-80,Arch Intern Med2006;166:772-80

Women with Severe Vasomotor Symptoms Increased risk for stroke Increased aortic calcification Reduced flow mediated arterial dilatation Rossouw, JAMA 2007;297:1265-1477, Thurston, Circulation 2008;118: 1234-1240

WHI-YET MORE NSS SUBGROUP FINDINGS Hazard Ratios at 5 years Regimen Event Women with mod to severe flushes Women with no or mild flushes E+P CHD HR 1.87 HR 1.44 E+P Stroke HR 2.23 HR 1.33 E CHD HR 1.32 HR 1.00 LaCroix AZ Am J Med 2005;118:79S-87S

Hormone Replacement Therapy Cardiovascular Risk Cardiac risk from HRT is relatively low in the early postmenopausal woman HRT used early following menopause may slow deterioration in vascular function Stroke risk from HRT remains significant across all age bands HRT cardiovascular risk may be attenuated by the use of statins and aspirin HRT should be avoided in women with established CV disease There is no evidence that transdermal hormone preparations or bioidentical hormones convey a lower CV risk

Challenges in Improving Outcomes for Women with CAD Educate women and their families that they are at risk Maori and Pacific Island focussed education Better treatment of risk factors especially BP, DM, metabolic syndrome

Challenges in Improving Outcomes for Women with ACS Greater use of proven secondary prevention therapies on discharge from hospital and long term post discharge Cardiac rehabilitation better tailored to women s needs especially psychosocial support